Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 20/20 | 0.57 |
| ▸ | CBL | P22681 | 18/20 | 0.57 |
| ▸ | CBLC | Q9ULV8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22849886 | 1.00 | CBLB (0.57) | CBLBCBLCBLC | |
| SCHEMBL30598936 | 1.00 | CBLB (0.57) | CBLBCBLCBLC | |
| SCHEMBL30520987 | 0.91 | CBLB (0.49) | CBLBCBLCBLC | |
| SCHEMBL22832670 | 0.89 | CBLB (0.46) | CBLBCBLCBLC | |
| SCHEMBL25173620 | 0.89 | CBLB (0.46) | CBLBCBLCBLC | |
| SCHEMBL25179668 | 0.89 | CBLB (0.46) | CBLBCBLCBLC | |
| SCHEMBL25311764 | 0.89 | CBLB (0.47) | CBLBCBLCBLC | |
| SCHEMBL22851384 | 0.89 | CBLB (0.46) | CBLBCBLCBLC | |
| SCHEMBL25192736 | 0.89 | CBLB (0.47) | CBLBCBLCBLC | |
| SCHEMBL25311818 | 0.89 | CBLB (0.47) | CBLBCBLCBLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071475-A | Ternary condensed ring derivative and medical application thereof | 杭州百新生物医药科技有限公司 | 2026-05-22 | — | — | CN | disclosed |
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
| WO-2025243317-A1 | SUBSTITUTED BICYCLIC SULFONAMIDE DERIVATIVES AS MODULATORS OF CBL-B | JUBILANT BIOSYS LIMITED (IN) | 2025-11-27 | — | — | WO | disclosed |
| EP-4653436-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | GUANGZHOU YUFAN NANTU BIOTECHNOLOGIES CO., LTD (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| EP-4573085-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS | Glenmark Pharmaceuticals Limited (IN) | 2025-06-25 | — | — | EP | disclosed |
| CN-114364670-B | Substituted benzyl-triazole compound for Cbl-b inhibition and further application thereof | 纽力克斯治疗公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4558504-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-05-28 | — | — | EP | disclosed |
| EP-4558501-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2023151642-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023081853-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | GENENTECH, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023072273-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | 先声再明医药有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-3990117-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | Nurix Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114364670-A | Substituted benzyl-triazoles for Cbl-b inhibition and further uses thereof | 纽力克斯治疗公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210053961-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2020264398-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | CBLB 3/4885CBL 1/4885CBLC 2/4885 |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | CBLB 2/4885CBL 1/4885CBLC 3/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | CBLB 1/4885CBL 2/4885CBLC 3/4885 |
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | CBLB 1/4885CBL 2/4885CBLC 3/4885 |
| US-20210053961-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | CBLB 2/4885CBL 1/4885CBLC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.